ReviewCancer cell international2021
Recent advances of m
Review in Cancer cell international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Esophageal cancer: from pathogenesis to precision therapies.Signal transduction and targeted therapy · 2026Review
- Regulatory mechanisms of m6A RNA methylation in esophageal cancer: a comprehensive review.Frontiers in genetics · 2025Review
- KIAA1429 promotes the malignancy of oral squamous cell carcinoma by regulating CA9 m6A methylation.Cytotechnology · 2024Article
- Article
- Exosome-derived lncRNA A1BG-AS1 attenuates the progression of prostate cancer depending on ZC3H13-mediated m6A modification.Cell division · 2024Article
- Comprehensive analysis of m6A RNA methylation regulators in esophageal carcinoma.Translational cancer research · 2024Article
- Article
- The use of RNA-based treatments in the field of cancer immunotherapy.Molecular cancer · 2023Review
- N6-methyladenine-mediated aberrant activation of the lncRNA SOX2OT-GLI1 loop promotes non-small-cell lung cancer stemness.Cell death discovery · 2023Article
- Roles of oncogenes in esophageal squamous cell carcinoma and their therapeutic potentials.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- NJournal of hepatocellular carcinoma · 2023Article
- N6-methyladenosine (m6A) RNA modification in the pathophysiology of heart failure: a narrative review.Cardiovascular diagnosis and therapy · 2022Review
- Identification of clinical prognostic features of esophageal cancer based on m6A regulators.Frontiers in immunology · 2022Article
- METTL3/mFrontiers in pharmacology · 2022Article
- Emerging role of m6A methylation modification in ovarian cancer.Cancer cell international · 2021Review
- Analysis of NFrontiers in genetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
In recent years, with the development of RNA sequencing technology and bioinformatics methods, the epigenetic modification of RNA based on N
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.